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INTRODUCTION
Cardiovascular disease is the leading cause of death for pa-
tients with end-stage renal disease (ESRD). The increased risk
of cardiovascular mortality may be attributable to advanced
atherosclerotic vascular changes and left ventricular hypertro-
phy (1). The previous epidemiological and clinical studies have
shown that damage to large arteries may be a major factor that
contributes to the high rate of cardiovascular mortality for
patients with ESRD (2, 3). The increased sclerosis and stiff-
ness of the abdominal aorta reflect early atherosclerosis and
this is significantly correlated with coronary arteriosclerosis
(4, 5). Blacher et al. (3) reported that aortic stiffness predicts
all-cause mortality and cardiovascular mortality in patients
with ESRD, and this suggests that arterial wall stiffness may
be a good predictor of cardiovascular mortality in ESRD pati-
ents. Therefore, evaluating the arterial pathophysiologic char-
acteristics is critical for the early detection and prevention of
atherosclerosis.
Pulse wave velocity (PWV) represents a valid noninvasive
method for assessing asymptomatic atherosclerosis or arteri-
al stiffness. The elastic properties of the aorta are important
determinants of cardiovascular events, and the PWV measured
along the aortic pathway is quite clinically relevant (6). Sev-
eral studies have reported that the PWV was a strong inde-
pendent predictor of the overall and cardiovascular mortali-
ty of hemodialysis patients (6, 7). Left ventricular hypertro-
phy (LVH) is the most frequent cardiac abnormality and it is
a strong, independent risk factor for the cardiovascular mor-
bidity and mortality of dialysis patients. Increased arterial
stiffness is associated with an increased left ventricular over-
load, which may be associated with left ventricular hypertro-
phy in patients with ESRD (8). These results support the hy-
pothesis that measurement of the aortic PWV could help not
only for assessing LVH, but also for predicting cardiovascular
mortality. However, the relationship among aortic stiffness,
left ventricular hypertrophy and cardiovascular mortality has
not been fully evaluated for dialysis patients.
The purpose of the present study was to assess the factors
that contribute to aortic stiffness and to investigate whether
increased arterial stiffness, as assessed by the aortic pulse wave
velocity, affects the cardiac alteration in hemodialysis patients.
We also studied the relationship between the aortic PWV and
cardiovascular events. 
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The Impact of the Aortic Pulse Wave Velocity on the Cardiovascular
Outcomes of Hemodialysis Patients
The aims of our study were to identify the risk factors for an increased aortic pulse
wave velocity (AoPWV) and to assess the impact of the AoPWV on the cerebro-car-
diovascular (CV) outcomes of hemodialysis (HD) patients. Seventy two HD patients
were included, and the AoPWV, the echocardiography and the biochemical param-
eters were measured. After dividing the patients into tertiles according to the AoPWV
values, we defined the low, the middle and the high AoPWV groups. The patients in
the high AoPWV group showed a significantly higher age and high-sensitivity C-reac-
tive protein level, a greater prevalence of diabetes and statin use, left ventricular
hypertrophy, average pulse pressure (PP), AoPWV and left ventricular mass index
and a lower serum albumin level than those in the low AoPWV group (p<0.05). On
multivariate regression analysis of the AoPWV, age and the average PP were
independently related to the AoPWV (p<0.05). On the multivariate Cox analysis
for CV outcomes, the AoPWV and the average PP remained significant indepen-
dent predictors of CV events. Our data suggest that an increased AoPWV is an
independent predictor for the CV outcomes of HD patients.
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Patients
A total of seventy two patients with ESRD and who had
been on intermittent hemodialysis treatment for more than
6 months at our hospital were included in this study. All the
subjects gave us their informed consent after receiving writ-
ten explanation about the study. Cross-sectionally, we mea-
sured pulse wave velocity, and we performed 24 hr ambula-
tory blood pressure monitoring and echocardiography. We
excluded those patients with severe illness such as malignan-
cy, liver cirrhosis, present myocardial, cerebrovascular or periph-
eral vascular disease, previous history of cardiovascular disease
within 6 months prior to study and apparent acute infection.
The patients received hemodialysis treatment 4 hr/session
three times a week during the study period. First-use hemo-
phane (GFr12 Plus; Gambro, Tokyo, Japan) was used for he-
modialysis. The following characteristics were measured or
calculated: age, gender, the body mass index (BMI), the dura-
tion of hemodialysis, Kt/V, the presence of diabetes mellitus,
the presence of statin use, the number of anti-hypertensive
drugs used (angiotensin converting enzyme inhibitor, angio-
tensin receptor blocker, calcium channel blocker, beta-block-
er, alpha-blocker, direct acting anti-hypertensive drug) and
the smoking history.
Biochemical assays
Biochemical parameters including lipid profiles were mea-
sured by using routine laboratory methods. The serum intact
parathyroid hormone (iPTH, the Nicholas immunoradiomet-
ric assay) and the serum high-sensitivity C-reactive protein
(hs-CRP, Latex Immunoturbidometry) were measured. The
level of low-density lipoprotein (LDL) cholesterol was calcu-
lated using the Friedewald formula. All the blood samples for
biochemical assays were drawn in the morning at the begin-
ning of the dialysis session.
Measurement of the pulse wave velocity
All the measurements of PWV were performed using an
applanation tonometer (PP-1000, Hanbyul Meditech Co.,
Seoul, Korea). The PWV was determined as the difference in
travel time of the pulse-wave between two different record-
ing sites and the heart, divided by the travel distance of the
pulse-wave form. An electrocardiogram (ECG) was used to
determine the start of the pulse-wave. The mean of 10 sec of
the tonometer recorded pulse-waves at the femoral and carotid
arteries (aortic PWV) was used to determine the arrival of the
pulse-wave at the peripheral recording site. The distances were
measured as straight lines between the sternal notch and the
points of applanation with using a tape measure, with the tran-
sit distance defined as the distance from the sternal notch to
the femoral artery minus the distance from the sternal notch
to the carotid artery (9, 10).
Ambulatory blood pressure monitoring and
echocardiography
Twenty four hour ambulatory blood pressure monitoring
(24 h-ABPM) was performed between two dialysis sessions
with using an ambulatory blood pressure monitor (Oscar
oscillometric ambulatory blood pressure monitor, SunTech
Medical, NC, U.S.A.). It was programmed to measure the
blood pressure every 30 min from 6:00 to 20:00 (daytime)
and from 20:00 to 6:00 (nighttime). The 24 h-ABPM vari-
ables included the average systolic blood pressure (SBP), the
mean arterial blood pressure (MAP), the diastolic blood pres-
sure (DBP), the heart rate (HR) and the pulse pressure (PP).
The blood pressure thresholds were 135/85 mmHg (day-
time mean blood pressure) or 120/75 mmHg (nighttime
mean blood pressure); that is, the average recordings at or
over these levels were classified as hypertension. For all the
patients, antihypertensive drugs, coronary vessel dilators,
anti-platelet agents, lipid lowering agents and erythropoietin
were continuously administered during the study.
Two-dimensional echocardiography was performed with the
subjects in the left decubitus position (Sonos 5500, Hewlett-
Packard, Andover, MA, U.S.A.). A single experience cardi-
ologist, who was unaware of the clinical details of the patients,
performed the measurements. The left ventricular mass (LVM)
was corrected by the body surface area, and it was expressed
as the LVM index (LVMi); the left ventricular end-diastolic
volume (LVEDV), interventricular septal thickness (IVST),
left ventricular posterior wall thickness (LVPWT), left atrial
diameter (LAD) and left ventricular ejection fraction (LVEF)
were calculated according the recommendations of the Amer-
ican Society of Echocardiography (11). The LVM was calcu-
lated according to the Devereux formula and it was indexed
to height2.7 (LVMi). LVH was defined by a LVMi of over 47
g/m2.7 in women or a LVMi over 50 g/m2.7 in men (12). 
Statistical analysis
The data is expressed as means±SD. Chi square tests and
ANOVA tests were used. The correlation between the vari-
ables were tested by Pearson’s rank correlation test (r=corre-
lation coefficient). We also used multivariate linear regression
analysis to assess the linear associations between the AoPWV
and the determinants of the clinical, biochemical and echocar-
diographic parameters of the study’s patients. Cox’s proportion-
al hazard regression analysis was used to compare the hazard
ratios between the patients with or without cardiovascular
events. The survival curves were estimated by the Kaplan-Meier
product-limit method and they were compared by the log
rank test. Statistical analysis was performed using SPSS soft
ware, version 11.0 (SPSS, Inc., Chicago, IL, U.S.A.). A p value
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RESULTS
Baseline characteristics of the hemodialysis patients
The mean age of the patients at inclusion was 50.4±13.0
yr (range: 26-75 yr) and the mean duration of dialysis treat-
ment was 46.7±33.6 months (range: 8-180 months). Four-
ty-two patients (58.3%) were men, and 33 of the patients
(45.8%) had diabetes. The majority of our patients reported
a history of hypertension, with 75% receiving antihyperten-
sive therapy (mean 1.8±1.5 antihypertensive medications).
Fifty patients (69.4%) received RAS blockade (angiotensin
converting enzyme inhibitor, ACEI or angiotensin receptor
blocker, ARB) and 22 patients received statins (30.5%).
The mean aortic pulse wave velocity of the patients was
8.09±1.12 m/sec.
Analysis of the aortic pulse wave velocity according to
the patient groups
We divided our population into tertiles with respect to their
AoPWV value, and then grouped the patients according to
the tertiles: the low AoPWV group (the first tertile, AoPWV
value <7.4 m/sec, n=24), the middle AoPWV group (the
second tertile, AoPWV value 7.4-8.2 m/sec, n=24) and the
high AoPWV group (the third tertile, AoPWV value >8.2
m/sec, n=24). Comparison of the clinical and biochemical
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*p<0.05 vs. the low AoPWV group; 
� p<0.05 vs. the low and middle AoPWV group.
The values represent means±SDs. BMI, Body mass index; RAS blockade, renin-angiotensin blockade (angiotensin converting enzyme inhibitor or angiotensin
receptor blocker); iPTH, intact parathyroid hormone; hs-CRP, high sensitivity C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure;
MAP, mean arterial blood pressure; HR, heart rate; PP, pulse pressure; AoPWV, aortic pulse wave velocity; LVMi, left ventricular mass index; IVST, interventricu-
lar septal thickness; LVPWT, left ventricular posterior wall thickness; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume;
LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy.
Parameters Low AoPWV (n=24) Middle AoPWV (n=24) High AoPWV (n=24)
Male (%) 13 (54.2) 14 (58.3) 15 (62.5)
Age (yr) 46.2±12.9 47.5±13.6 59.0±7.7
�
BMI (kg/m
2) 20.8±3.8 20.4±2.6 21.0±2.1
Current smokers (%) 6 (25.0) 6 (25.0) 9 (37.5)
Diabetes (%) 7 (29.2) 10 (41.7) 16 (66.7)*
RAS blockade use (%) 17 (70.8) 13 (54.2) 20 (83.3)
Statin use (%) 4 (16.7) 8 (33.3) 10 (41.7)*
Dialysis duration (mo) 39.1±22.4 49.0±33.8 52.4±42.7
Kt/V 1.25±0.19 1.37±0.27 1.34±0.28
Hematocrit (%) 30.5±3.1 30.5±3.1 29.1±2.8
Albumin (g/dL) 4.2±0.4 4.2±0.3 3.8±0.4*
Total cholesterol (mg/dL) 162.4±40.6 166.5±30.6 173.8±34.0
Triglyceride (mg/dL) 118.5±63.0 163.6±67.2 145.2±74.1
LDL-cholesterol (mg/dL) 73.2±29.7 79.8±31.5 90.9±28.4
Calcium (mg/dL) 9.4±0.7 9.1±0.9 9.7±0.8
Phosphorus (mg/dL) 4.4±1.3 4.3±1.8 3.7±1.1
Ca×P 41.8±13.0 39.4±16.7 35.3±10.4
iPTH (pg/mL) 100.3±137.8 125.9±71.2 85.0±42.3
hs-CRP (mg/L) 0.94±0.60 1.65±2.10 2.87±2.92
�
Average SBP (mmHg) 137.4±19.0 129.9±19.4 138.8±15.7
Average DBP (mmHg) 78.6±11.5 79.4±10.9 78.6±9.6
Average MAP (mmHg) 105.3±16.2 102.8±12.4 109.0±12.8
Average HR (n/min) 74.1±11.0 73.1±11.2 72.1±9.4
Average PP (mmHg) 54.7±17.1 53.4±13.5 66.5±7.0
�
AoPWV (m/s) 7.09±0.26 7.81±0.21* 9.47±0.84
�
LVMi (g/m
2.7) 43.9±12.4 44.4±12.1 54.7±11.0
�
IVST (mm) 12.5±3.7 13.4±2.8 13.7±1.9
LVPWT (mm) 13.2±2.1 13.3±2.0 13.5±1.4
LVEDV (mm) 88.7±23.5 92.7±26.7 91.4±22.7
LVESV (mm) 35.8±11.2 35.4±12.2 39.8±13.2
LAD (mm) 38.9±4.2 39.2±4.1 41.7±4.4
LVEF (%) 63.2±5.4 63.1±5.5 62.4±6.8
LVH (%) 4 (16.7) 9 (37.5) 16 (66.7)
�
Table 1. The main characteristics of the patient population at baseline according to the groups of aortic pulse wave velocityparameters among groups is shown in Table 1. The mean val-
ues of age at inclusion, the serum hs-CRP, the average PP,
the average Ao PWV, LVMi and the prevalence of LVH for
the high AoPWV group were significantly higher than those
of any other group (p<0.05). Likewise, the prevalence of dia-
betes and statin use showed significantly higher values for the
high AoPWV group than those of the low AoPWV group
(p<0.05). In contrast, serum albumin was significantly
lower for the high AoPWV group compared with that of the
low AoPWV group (p=0.02). There were no significant dif-
ferences between the two groups for gender, BMI, the num-
ber of smokers, medication of ACEI or ARB, the duration of
dialysis, the adequacy of dialysis (Kt/V), the values of the
hematocrit, total cholesterol, triglyceride, LDL-cholesterol,
phosphorus, the products of calcium and phosphorus,
iPTH, the average MAP, DBP and HR and the echocardio-
graphic parameters, except for the LVMi.
Association between AoPWV and clinical parameters
Pearson’s correlation test was performed to examine the
relationships between AoPWV and the clinical parameters.
The AoPWV value was positively correlated with age (r=0.40,
p=0.01), the presence of diabetes (r=0.27, p=0.04), the serum
calcium (r=0.31, p=0.02), the hs-CRP (r=0.38, p=0.01), the
average pulse pressure (r=0.38, p=0.01), the LVMi (r=0.24,
p=0.03) and the LAD (r=0.22, p=0.04), but the AoPWV value
was negatively correlated with the serum albumin levels (r=
-0.31, p=0.02) and the LVEF (r=-0.26, p=0.03). However,
there were no significant correlations between the AoPWV
and the other parameters, such as the use of RAS blockade
or statin, serum levels of total cholesterol, triglyceride, LDL-
cholesterol, phosphorus, the products of calcium and phos-
phorus, iPTH, the average DBP, MAP, and HR and the ec-
hocardiographic parameters, except for the LVMi and the LAD
(data not shown). Multivariate linear regression analysis indi-
cated that age (β =0.362, p=0.013) and the average PP (β =
0.324, p=0.025) were independently associated with the Ao
PWV values (R
2=0.297, p=0.001) (Fig. 1).
Cardiovascular outcomes
We followed up the patients for a mean of 46±33 months
(range: 12-46 months). A total of 26 fatal or non-fatal cere-
bro-cardiovascular (CV) events were recorded. Eighteen events
were cerebral infarction, five were coronary artery disease (unsta-
ble angina 3, myocardial infarction 2) and three were cerebral
hemorrhage. Two patients had both unstable angina and cere-
bral infarction.
Univariate Cox proportional hazards analysis showed that
age (p=0.016), the serum albumin (p=0.012), the hs-CRP (p=
0.022), the average MAP (p=0.033), the average PP (p=0.001),
the AoPWV (p=0.001), the LVMi (p=0.024), the LVEF (p=
0.001), the LAD (p=0.003) and the LVESV (p=0.003) were
significant predictors of CV events. There was not statistical
significance in gender, the time on dialysis before inclusion,
the presence of diabetes and the average systolic blood pres-
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This model included age, diabetes, albumin, total cholesterol, triglyceride,
LDL-cholesterol, calcium, phosphorus, Ca x P, iPTH, hs-CRP, average
systolic pressure, average diastolic blood pressure, average mean arte-
rial pressure, average heart rate, average pulse pressure, left ventricu-
lar mass index, interventricular septal thickness, left ventricular posteri-
or wall thickness, left ventricular end-diastolic volume, left ventricular end-
systolic volume, left atrial diameter and left ventricular ejection fraction
(model; p=0.001, R
2=0.297). Diabetes mellitus was used as dummy
variable. Diabetes mellitus and non-diabetes mellitus were assigned
values of 1 and 0, respectively. PP, pulse pressure.
β T p
Age 0.362 2.604 0.013
Average PP 0.324 2.328 0.025
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p=0.01sure. On the multivariate Cox proportional hazards analysis,
the AoPWV (p=0.018) and the average PP (p=0.004) remained
the significantly independent predictors of CV outcomes
(Table 3). Fig. 2 shows the probability of cardiovascular sur-
vival according to the AoPWV groups. Comparison between
the survival curves was highly significant (log-rank test, chi
square=26.5; p<0.0001).
DISCUSSION
Increased arterial stiffness (reduced arterial compliance) seems
to have a critical role in the development of high SBP, a widened
PP, left ventricular work overloading and hypertrophy and
increased CV mortality (13). The mechanisms for increased
arterial stiffness in patients with uremia are not fully under-
stood, but they may include fluid overloading, arterial calci-
fication, inflammation, activation of sympathetic nervous activ-
ity, activation of the renin-angiotensin system and increased
lipid oxidation and oxidative stress. Structural changes in the
large arteries are characterized by dilation, wall thickening
and calcifications, and these changes are more frequent in
ESRD patients (13).
In this study, the AoPWV was significantly associated with
age, the presence of diabetes, the hs-CRP, the serum albumin
and calcium and the average PP. These findings are consistent
with several previous studies (14, 15). In our study, the inde-
pendent parameters that were entered into the multivariate
linear regression analysis of the AoPWV were age and aver-
age PP.
The aortic PWV increases with age and the systolic blood
pressure, and so it should be considered accordingly. Previ-
ous studies on ESRD patients have shown that arterial stiff-
ness is enhanced independently of age and the systolic blood
pressure (16). Our data is consistent with several reports show-
ing a significant association between age and aortic stiffness
(13, 16). Age is known to be a more important contributing
factor to the central (aortic) PWV than to the peripheral (br-
achial) PWV (6, 17). Age also seems to plays a more critical
role for aortic stiffness in the older dialysis population than
in the relatively young dialysis population. Although a pre-
vious study by Covic et al. (13) failed to demonstrate a sig-
nificant correlation between age and aortic stiffness, the mean
age of our patients was higher than that of their study (50.4
±13.5 vs. 42.6±11.2 yr, respectively). Our results failed
to show a relationship between AoPWV and the average
(p=0.07). The majority of our patients receiving hemodialy-
sis reported a history of hypertension, with 75% receiving
antihypertensive therapy. So, the effect of drugs for the treat-
ment of hypertension should be considered when interpret-
ing our results.
It is well known that most patients with ESRD have LVH
or systolic dysfunction. Some studies reported that an increased
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Adjustments were made for age at inclusion, gender, the time on dialysis before inclusion, diabetes and the average systolic blood pressure.
HR, hazard ratio per 1SD increment; CI, confidence interval; hs-CRP, high sensitivity C-reactive protein; MAP, mean arterial blood pressure; PP, pulse pres-
sure; AoPWV, aortic pulse wave velocity; LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; LVESV, left ventricu-
lar end-systolic volume.
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.05 1.01-1.09 0.016 1.09 0.99-1.15 0.947
Albumin 0.28 0.10-0.76 0.012 1.07 0.08-14.11 0.094
hs-CRP 1.18 1.03-1.37 0.022 1.16 0.91-1.45 0.236
Average MAP 1.03 1.00-1.05 0.033 1.02 0.98-1.07 0.284
Average PP 1.12 1.05-1.19 0.001 1.13 1.04-1.22 0.004
AoPWV 2.07 1.54-2.79 0.001 1.73 1.10-2.72 0.018
LVMi 1.03 1.00-1.06 0.024 0.98 0.90-1.02 0.532
LVEF 0.89 0.84-0.95 0.001 1.01 0.84-1.22 0.891
LAD 1.13 1.04-1.22 0.003 0.97 0.83-1.13 0.666
LVESV 1.07 1.03-1.10 0.001 1.02 0.98-1.16 0.284
Table 3. Cox proportional hazard regression analysis for cardiovascular outcomes 
Fig. 2. Kaplan-Meier survival curves according to the aortic pulse















































Middle AoPWW groupAoPWV has been observed in ESRD patients and this is direct-
ly related to the magnitude of the LVH (18, 19). The increased
arterial stiffness raises the systolic blood pressure and pulse
pressure, thereby causing an increased left ventricular after-
load and altered coronary perfusion. We demonstrated a weak,
but significant correlation of AoPWV with the LVMi and
LVEF in hemodialysis patients, which suggests that arterial
stiffness may contribute to the development of LVH in these
patients. However, we did not show an independent associ-
ation between AoPWV and the LVMi on the multivariate
linear regression analysis.
A previous study has shown that the increased aortic PWV
was predictive of adverse cardiovascular outcomes, indicat-
ing that arterial stiffness is not only a marker of established
and more advanced arterial changes, but it is also a risk fac-
tor that contributes to the development of cardiovascular dis-
ease (20). The studies of hemodialysis patients have reported
that the PWV independently predicted all-cause and cardio-
vascular mortality (7). The present study supports the previ-
ous findings of PWV as a predictor for cardiovascular mor-
tality (6, 9). In this study, after adjustment for all the other
cardiovascular risk factors (including age, gender, the aver-
age SBP and the presence of diabetes), the AoPWV and the
average PP were significant independent predictors of the car-
diovascular outcome. For each PWV increase of 1 standard
deviation, the cardiovascular events hazard ratio was 1.73 (95
% CI, 1.10 to 2.72). Another important finding in our results
is that the AoPWV remained independent predictors of car-
diovascular events in spite of the presence of influence by an
important confounder, the LVMi. The results of a previous
study by Blacher et al. (6) showed that the PWV was a strong
predictor of survival for ESRD patients on the multivariate
Cox proportional analysis with using all the variables, includ-
ing the LVH. As is well known, an increased LVMi and LVH
are potent predictors of cardiovascular mortality for hemodi-
alysis patients. The reason why the present result was revealed
is unclear. A possible explanation of this result is that most
of the cardiovascular events in our study were cerebrovascu-
lar accidents, and mainly cerebral infarction. Eighteen car-
diovascular events (69.2%) were cerebral infarction in our
population, and only five (19.2%) were cardiac events. Aor-
tic stiffness is vascular change and this is associated with ath-
erosclerosis and arterial calcification. So, we think that prior
to cardiac alteration, arterial stenosis or occlusion more fre-
quently develops before cardiac events occur.
Another interesting finding in the present study is that the
average PP had significant correlation with the AoPWV and
it was an independent predictor of cardiovascular events. Zureik
et al. (21) insisted that the increased pulse pressure causes
hemodynamic barotrauma to the vascular wall, which causes
endothelial damage and inflammation, and the final result is
atherosclerosis or arterial stiffness. Furthermore, Safar et al.
(14) have shown that the carotid PP (a close surrogate of the
aortic PP), the ratio of the brachial PP to the carotid PP and
the PWV are all significant independent predictors of all-
cause mortality. These results provide evidence of the clini-
cal utility of measuring the PP together with the PWV in
hemodialysis patients for predicting cardiovascular morbidi-
ty and mortality.
Our study has several limitations. First, the size of this study
was relatively small and the follow up period was shorter than
that of other studies. As was previously described, we failed
to show the association between AoPWV and the average SBP
which is an important contributing factor for aortic stiffness.
We think that a large cohort and a long period study are need-
ed to prove the correlation of both parameters. Second, in our
results, we did not find enough cardiac morbidity such as atri-
al fibrillation, congestive heart failure or systolic dysfunction.
This may be one of the reasons why the LVMi did not remain
an independent predictor of cardiovascular events. Third, the
patients’ treatment was not standardized during the follow-
up period. Our study did not show a significant correlation
of AoPWV with the lipid profiles or calcium and phospho-
rus levels, which are important for arterial calcification or as
atherosclerotic risk factors. In addition, although the preva-
lence of the use of statin was higher in the high AoPWV group
than that in the low AoPWV group, we failed to demonstrate
the association between AoPWV and the use of RAS block-
ade or statin. Previous studies reported that RAS blockades
or statin improve arterial stiffness in type 2 diabetes or essen-
tial hypertension (22, 23). Although it is practically impos-
sible to do in such complex patients who are followed for long
periods of time, the effect of drugs on the treatment for hyper-
tension with RAS blockade, for dyslipidemia with statin or
for the calcium and phosphorus metabolism should be con-
sidered in this kind of study. Fourth, in this study, we eval-
uated arterial stiffness of patients with aortic PWV and brachial
PP. Recently, two highly reproducible markers of aortic stiff-
ness-aortic PWV and augmentation index (AIx)-have been
shown to be strong CV morbidity predictors for patients on
haemodialysis (24). The AIx is the one of the methods for
arterial stiffness using arterial wave reflections and provides
a measure of systemic arterial stiffness (25, 26). There are some
reports demonstrated that AIx is more reliable method for
evaluating arterial stiffness than PWV, and it can be affect-
ed by multiple factors such as blood pressure, age, gender,
height and heart rate (27, 28). On the other hand, peripher-
al pulse pressure does not always predict central pulse pres-
sure, which is important because central, not brachial artery,
pressure best defines left ventricular workload and, thus, an
important and independent predictor of cardiovascular mor-
tality. Central PP (carotid artery or ascending aorta) has shown
an independent predictive value for all-cause mortality in
patients with end-stage renal disease and in the hypertensive
patients (29). But some studies reported that aortic PWV is
highly correlated with AIx, and a decline in endothelial func-
tion is associated with increased large artery stiffness, wave
reflections, and central pulse pressure (30, 31). So, we think
S126 S.J. Shin, Y.K. Kim, S. Chung, et al.that further study including PWV, AIx and central PP con-
comitantly for evaluating aortic stiffness should be needed in
dialysis population.
In conclusion, the present study shows that the AoPWV
is independently associated with age and pulse pressure, and
it is a significant predictor of the cardiovascular outcome for
patients who are on maintenance hemodialysis. Our results
support the hypothesis that measurement of the aortic PWV
could help not only for risk assessment, but also for creating
risk reduction strategies by monitoring the arterial stiffness
of patients who are under different drug regimens.
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